
Ramantamig trispecific shows deep, durable myeloma responses, with tocilizumab easing CRS and enabling safer outpatient dosing.

Ramantamig trispecific shows deep, durable myeloma responses, with tocilizumab easing CRS and enabling safer outpatient dosing.

September 27th 2026